MELISSA MARIA MILITO

Ms. MELISSA MARIA MILITO

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMELISSA MARIA MILITO
MELISSA MARIA MILITO
MCMattia Chiesa
Mattia Chiesa
AMAlice Mallia
Alice Mallia
GPGiulia G. Papaianni
Giulia G. Papaianni
JRJulia Theresa Regalado
Julia Theresa Regalado
PGPablo José Giraudi
Pablo José Giraudi
Chronic low-grade inflammation is a key feature of obesity-associated dysglycemia, yet substantial heterogeneity exists in inflammatory responses among individuals with normoglycemia, prediabetes, and type 2 diabetes mellitus (T2DM). Whether circulating inflammatory protein profiles define distinct patient phenotypes beyond conventional glycemic classification remains incompletely understood. In this cross-sectional analysis of 142 individuals with severe obesity, plasma inflammatory proteins were quantified using Olink proximity extension assay technology. Subjects were stratified by glycemic status (noDM, normoglycemia; PreDM, prediabetes and T2DM) while maintaining comparable distributions of metabolic dysfunction-associated steatotic liver disease. Differential expression analyses were performed across glycemic groups, and unsupervised topological data analysis (TDA) was applied to identify inflammatory protein-based patient subgroups. Several inflammatory proteins were significantly upregulated in T2DM and PreDM compared with noDM, with interleukin-8 (IL-8), Fms-relatedlike tyrosine kinase 3 ligand (Flt3L), and CUB domain containing protein (CDCP1) showing the largest significant differences. NPX distributions of these proteins exhibited gradual increases across glycemic stages with substantial inter-individual variability. TDA identified seven clusters defined by distinct inflammatory protein signatures. One cluster was enriched for individuals with T2DM and characterized by coordinated upregulation of IL-8, Flt3L, CDCP1, and additional immune- and cytokine-related proteins, whereas other clusters displayed alternative inflammatory profiles that were not explained by glycemic status alone. Inflammatory proteomic profiling in severe obesity reveals both glycemia-associated protein changes and distinct inflammatory phenotypes that transcend conventional clinical classification. Integration of differential expression analysis with TDA highlights heterogeneity in inflammatory states, supporting a hypothesis-generating framework for future studies aimed at validating these proteomic patterns and clarifying their longitudinal relevance in obesity-related dysglycemia.

Verified
Journal Article
Open access
PDF file
MMMELISSA MARIA MILITO
MELISSA MARIA MILITO
MMMilos Mihajlovic
Milos Mihajlovic
AMAlice Mallia
Alice Mallia
SGStefania Ghilardi Ghilardi
Stefania Ghilardi Ghilardi
CTClaudio Tiribelli
Claudio Tiribelli
PGPablo José Giraudi
Pablo José Giraudi
Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to comorbidities like obesity, type 2 diabetes, and cardiovascular disease. Given that liver biopsy is the diagnostic gold standard, there is a critical need for minimally invasive tests, particularly for the inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH). In this discovery study, we investigated the plasma proteome to identify blood biomarkers for MASH and explored their potential tissue sources, the liver and visceral adipose tissue. Plasma low-abundance proteome profiling was performed on samples from a cohort of morbidly obese MASLD subjects (n = 90; 40 with MASH, 50 without) using Olink® panels. Paired liver and visceral adipose biopsies were also analyzed. Data showed 34 significantly different plasma proteins between the two groups, including Pleiotrophin (PTN), Fibroblast growth factor-21 (FGF-21), and Hepatocyte growth factor (HGF), among others. While plasma-tissue correlation was only found for STX8, PTN and FGF-21 demonstrated the strongest associations with the histopathological features of MASH. A diagnostic model combining PTN, FGF-21, and AST achieved a robust AUC of 0.88 (95% CI: 0.84–0.97) for distinguishing MASH. Based on this discovery pilot study, circulating PTN and FGF-21 emerge as promising non-invasive biomarkers for improving patient stratification and supporting therapeutic evaluation in MASH, warranting validation in independent cohorts and future studies.